These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32915523)

  • 21. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
    Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
    Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.
    Anker SD; Sander LE; Fitchett DH; Zinman B; Pernille Ofstad A; Wanner C; Vedin O; Lauer S; Verma S; Yaggi HK; Inzucchi SE
    Diabetes Res Clin Pract; 2022 Apr; 186():109837. PubMed ID: 35314257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.
    Neeland IJ; Eliasson B; Kasai T; Marx N; Zinman B; Inzucchi SE; Wanner C; Zwiener I; Wojeck BS; Yaggi HK; Johansen OE;
    Diabetes Care; 2020 Dec; 43(12):3007-3015. PubMed ID: 33004464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study.
    Thiele K; Rau M; Hartmann NK; Möllmann J; Jankowski J; Böhm M; Keszei AP; Marx N; Lehrke M
    Diabetes Obes Metab; 2021 Dec; 23(12):2814-2818. PubMed ID: 34378852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia.
    Ji Q; Ji L; Mu Y; Zhao J; Zinman B; Wanner C; George JT; Zwiener I; Ueki K; Yokote K; Ogawa W; Johansen OE
    Diabetes Obes Metab; 2021 Aug; 23(8):1886-1891. PubMed ID: 33950573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial.
    Odutayo A; Zinman B; Wanner C; Zwiener I; Lund SS; Hantel S; Fitchett D; Udell JA;
    CJC Open; 2024 Jul; 6(7):868-875. PubMed ID: 39026628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
    Abraham WT; Ponikowski P; Brueckmann M; Zeller C; Macesic H; Peil B; Brun M; Ustyugova A; Jamal W; Salsali A; Lindenfeld J; Anker SD;
    Eur J Heart Fail; 2019 Jul; 21(7):932-942. PubMed ID: 31218819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond.
    Oral EA
    Drugs Context; 2016; 5():212299. PubMed ID: 27648101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial.
    Wanner C; Inzucchi SE; Zinman B; Koitka-Weber A; Mattheus M; George JT; von Eynatten M; Hauske SJ;
    Diabetes Obes Metab; 2020 Dec; 22(12):2335-2347. PubMed ID: 32744354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
    Fitchett D; Zinman B; Wanner C; Lachin JM; Hantel S; Salsali A; Johansen OE; Woerle HJ; Broedl UC; Inzucchi SE;
    Eur Heart J; 2016 May; 37(19):1526-34. PubMed ID: 26819227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers.
    Tye SC; de Vries ST; Wanner C; Denig P; Heerspink HJL
    Front Pharmacol; 2021; 12():786706. PubMed ID: 35145402
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of empagliflozin in patients with diabetes and heart failure.
    Pham D; Albuquerque Rocha N; McGuire DK; Neeland IJ
    Trends Cardiovasc Med; 2017 Feb; 27(2):144-151. PubMed ID: 27612553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial.
    Ferreira JP; Verma S; Fitchett D; Ofstad AP; Lauer S; Zwiener I; George J; Wanner C; Zinman B; Inzucchi SE
    Cardiovasc Diabetol; 2020 Nov; 19(1):200. PubMed ID: 33243221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
    Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
    Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey.
    Wong ND; Fan W; Pak J
    Diab Vasc Dis Res; 2020; 17(4):1479164120945674. PubMed ID: 32722930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial.
    Pellicori P; Fitchett D; Kosiborod MN; Ofstad AP; Seman L; Zinman B; Zwiener I; Wanner C; George J; Inzucchi SE; Testani JM; Cleland JGF
    Eur J Heart Fail; 2021 Jul; 23(7):1085-1093. PubMed ID: 34031968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome: Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria.
    Verma S; Kosmopoulos A; Bhatt DL; Fitchett D; Ofstad AP; Wanner C; Mattheus M; Zinman B; Lawler PR; Leiter LA
    Am J Prev Cardiol; 2023 Sep; 15():100510. PubMed ID: 37384110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk].
    Scheen AJ
    Rev Med Liege; 2015 Nov; 70(11):583-9. PubMed ID: 26738271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.